Heavy smoking increases early mortality risk in patients with hepatocellular carcinoma after curative treatment - PubMed (original) (raw)
Heavy smoking increases early mortality risk in patients with hepatocellular carcinoma after curative treatment
Jaejun Lee et al. J Liver Cancer. 2024 Sep.
Abstract
Backgrounds/aims: Although cigarette smoking has been associated with an increased risk of hepatocellular carcinoma (HCC), its association with HCC mortality remains underexplored. We aimed to evaluate the effect of smoking on early mortality in HCC patients following curative treatment.
Methods: Data from the Korean Primary Liver Cancer Registry were examined for HCC patients who underwent liver resection or radiofrequency ablation between 2015 and 2018. Smoking cumulative dose was assessed in pack-years. The primary outcome was the 3-year overall survival (OS).
Results: Among 1,924 patients, 161 were classified as heavy smokers (≥40 pack-years). Heavy smokers exhibited a lower 3-year survival rate (77.1%) than nonsmokers (83.3%), with a significant difference observed in the 3-year OS (P=0.016). The assessment of smoking pack-years in relation to 3-year OS revealed a dose-dependent pattern, with the hazard ratio exceeding 1.0 at 20 pack-years and continuing to rise until 40 pack-years, reaching peak at 1.21 (95% confidence interval, 1.01-1.45). Multivariate Cox-regression analysis revealed heavy smoking, age ≥60 years, underlying cirrhosis, tumor size >3 cm, vascular invasion, and Child-Pugh class B/C as risk factors for 3-year OS. Subgroup analyses of patients with a tumor size <3 cm, absence of vascular invasion, and meeting the Milan criteria also showed inferior outcomes for heavy smokers in all three subgroups.
Conclusions: Heavy smoking, defined as a history of >40 pack-years, was linked to poorer 3-year survival outcomes in HCC patients undergoing curative treatments, underscoring the importance of smoking cessation in this population.
Keywords: Carcinoma, hepatocellular; Hepatectomy; Mortality; Radiofrequency ablation; Smoking.
Conflict of interest statement
Conflicts of Interest
The authors declare no conflict of interest. The funders had no role in the study design, collection, analyses, interpretation of data, writing of the manuscript, or decision to publish the results.
Figures
Figure 1.
Flowchart of patient selection. HCC, hepatocellular carcinoma; RFA, radiofrequency ablation.
Figure 2.
Three-year survival of study populations depending on the pack-years of smoking. (A) Dose-dependent survival rate. (B) Comparison between non-heavy smokers and heavy smokers. PY, pack-years; RMST, restricted mean survival time; RMTL, restricted mean time lost.
Figure 3.
Smoking dose-response curve of the hazard ratios for 3-year survival. CI, confidence interval; HR, hazard ratio; PY, packyears.
Figure 4.
Subgroup analysis of 3-year survivals between nonheavy smokers and heavy smokers. (A) HCC size less than 3 cm, (B) HCC without vascular invasion, and (C) HCC within Milan criteria. HCC, hepatocellular carcinoma.
References
- Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–249. - PubMed
LinkOut - more resources
Full Text Sources